Compare Mesoblast Limited (MESO) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Direxion Daily TSLA Bull 2X Shares — how do they compare? Mesoblast Limited trades at $14.28 (market cap $1.75B), while Direxion Daily TSLA Bull 2X Shares trades at $10.48 (market cap $3.97B). The key difference: Direxion Daily TSLA Bull 2X Shares is far larger — about 2.3× Mesoblast Limited's market cap, and Mesoblast Limited is more actively traded (239,027 versus 38,458,237). Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Direxion Daily TSLA Bull 2X Shares for 15 Days on average.
| MESO | TSLL | |
|---|---|---|
Market Cap | $1.75B | $3.97B |
Volume | 239,027 | 38,458,237 |
Sector | Health | Leveraged / Inverse |
52-Week High | $20.96 | $23.03 |
52-Week Low | $13.19 | $6.74 |
Typical Hold Time | 15 Days | 15 Days |
Enterprise Value | $1.83B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
TSLL (Direxion Daily TSLA Bull 2X Shares ETF) trades at $10.43, up 2.76% with neutral technical signals. The leveraged ETF tracks Tesla's daily performance, showing recent strength tied to Tesla's Cybercab event anticipation. Moving averages indicate bullish momentum while oscillators remain neutral, with RSI suggesting potential overbought conditions at shorter timeframes.
As a leveraged ETF, TSLL carries amplified risk from Tesla's volatility and daily reset mechanics. Recent news highlights both opportunity from Tesla catalysts and structural risks where investors can lose money even when Tesla rises. The ETF's performance depends entirely on Tesla's stock movement and market sentiment toward electric vehicle innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
